EORTC Gastrointestinal Cancer Group launches its Young Investigator’s Programme for 2018

The EORTC Gastrointestinal Cancer Group (GITCG) is launching its young investigator’s (YI) programme for the term 2018 to 2020. The aim of the YI programme is to develop a platform for innovative ideas, mentor future leaders of GI oncology and provide hands-on training for conducting international cancer research. The main requirements to be part of the programme are:

  • Become a member of the EORTC GI group
  • Any specialty is accepted
  • Age 45 and below
  • From any country (also from Eastern Europe, Scandinavian countries, Israel, Members of Japan Clinical Oncology Group, and Singapore)
  • With a committed mentor from his own institution who is an active member of the GI group
  • With a project proposal fitting to objectives and mission of the GI group

The mission of the GI group is to develop therapeutic strategies through innovative studies which are multidisciplinary, patient-centered and have a strong translational focus. It responds to the evolving landscape of cancer research by expanding its collaboration with different cancer research networks from Europe and Asia, enriching its pool of multidisciplinary experts and redesigning its young investigator’s programme to enable future leaders to be at the forefront of GI cancer research.

In parallel, it is launching a call for research proposals from interested young investigators specialized in GI cancer.  The focus of this call for proposals will be innovative projects from the SPECTAcolor: 2018updates. Projects related to gastroesophageal or biliary tract cancers may also submitted. A grant of a maximum of 50,000 euros shall be awarded to the best proposal. The submission criteria can be found in this link: GI Young investigator’s program 2018. To be eligible, the applicant must first apply to be a member of the EORTC GI group. This call will run until 30 June 2018 and the winner will be chosen on September 2018. Proposals can be submitted to

Back to news list

Related News

  • EORTC Completes Patient Recruitment to Study of Treatment for unresectable or metastatic melanoma

  • In Memoriam: Dr Martin Charles Mihm

  • The 1500th patient has been enrolled in the E²-RADIatE cohort OLIGOCARE (RP-1822)

  • PRESS RELEASE: Better treatment for better health: lifting the veil on treatment optimisation

  • Long-term follow-up of chemoradiotherapy treatment in glioma patients shows significantly increased survival

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older patients with acute myeloid leukemia

  • Pierre Fabre and EORTC open a large Phase III clinical study in the adjuvant setting of stage IIB-C melanoma

  • EORTC and Alliance Healthcare’s continued partnership in support of SPECTA clinical research infrastructure

  • Results of radiotherapy quality assurance in the PEACE-1 trial show high adherence to protocol

  • EORTC presents new precision medicine research results at AACR 2022